



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 30, 2019

Neil Kumar, Ph.D.  
Chief Executive Officer  
BridgeBio Pharma LLC  
421 Kipling Street  
Palo Alto, CA 94301

**Re: BridgeBio Pharma, Inc.**  
**Registration Statement on Form S-1**  
**Filed May 24, 2019**  
**File No. 333-231759**

Dear Dr. Kumar:

We have reviewed your registration statement and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments.

Registration Statement on Form S-1 filed on May 24, 2019

Prospectus Summary

Our Pipeline, page 4

1. Please add disclosure to your pipeline table to indicate that you have granted a third-party a currently-exercisable option to acquire PellePharm, including the product candidate BBP-009, and if the option is exercised you will no longer have any rights to BBP-009.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Neil Kumar, Ph.D.  
BridgeBio Pharma LLC  
May 30, 2019  
Page 2

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

You may contact Rolf Sundwall at 202-551-3105 or Mary Mast at 202-551-3613 if you have questions regarding comments on the financial statements and related matters. Please contact Christine Westbrook at 202-551-5019 or Erin Jaskot at 202-551-3442 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Maggie Wong, Esq.